التفاصيل البيبلوغرافية
| العنوان: |
Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. |
| المؤلفون: |
Cruijsen, M., van der Velden, W.J.F.M, de Haan, A.F.J., Klein, S. K., Hoogendoorn, M., Tromp, Y., de Valk, B., van Rees, B., de Boer, F., van der Spek, E., Pruijt, J., Verdonck, L.F., Vellenga, E., Blijlevens, N., van de Loosdrecht, A. A., Huls, G. |
| المصدر: |
Leukemia & Lymphoma; Nov2020, Vol. 61 Issue 11, p2752-2755, 4p |
| مصطلحات موضوعية: |
PATIENT compliance, BLOOD transfusion reaction |
| مستخلص: |
Several clinical studies have shown superiority of azacitidine compared to conventional care regimens in frail patients with MDS and AML [[1]]. In 57 (65%) of 87 patients without HI, and in 51 (81%) of the 63 patients that stopped treatment within 6 cycles, no BME was performed. In 13 out of 22 patients, the dose reduction was done before HI was reached, in 3 of them a BME was done before dose reduction (1 patient had CRi, and 2 patients had SD). Thirteen (6%) patients stopped treatment after the 1st cycle of azacitidine and 63 (37%) patients stopped within 6 cycles. [Extracted from the article] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
